KieferPix / Shutterstock.com
Biotechnology company Luc Therapeutics has agreed to licence its intellectual property covering its depression treatment to Novartis, stating that it will accelerate its programme into how to help people living with psychiatric diseases.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Luc Therapeutics; Novartis; biotechnology; depression; intellectual property